upgrade to Tier 1 to access blurred content, display up to 300 records, and unlimited CSV download
Data last updated 2024-04-28 04:05:40 -0500 US CDT
Insider Sentiment
| Company Name | Sector | Industry | Shares Outstanding(Mil) | 52-week High/Low | Period | Acq/Dsp Transaction Countb | Ids/Sec/Mkt Quantc | Acq/Dsp Shares Amountb | Acq/Dsp PctSOd |
|---|---|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | Health Care | Pharmaceuticals | 107.94 |
684.8
998.3
883.2
|
3-month |
0 / 19
|
|
0 / 41535
|
0.0 / 0.0 |
| 6-month |
0 / 35
|
|
0 / 84942
|
0.0 / 0.1 |
Data last updated 2024-04-27 07:55:23 -0500 US CDT
Major Shareholders
| Shareholder | Relation | Report Date | Holding Pct | Sharesa | Shares(Previous Report Date)a | Transactions (3 month)b | Transactions (6 month)b |
|---|---|---|---|---|---|---|---|
| Yancopoulos George | Bd. Co-Chair, President & CSO | 2024-02-20 | % | 1266978 (4.0%, 4.0%) | 1217856 (2024-01-04) |
C: 0 / 1
S: 0 / 16848 P: NA / 900.0 |
|
| Schleifer Leonard S | Bd. Co-Chair, President & CEO | 2023-12-13 | % | 695330 (1.8%, NA%) | 683016 (2023-05-17) | ||
| Vagelos P Roy | Director | 2023-04-05 | % | 467104 (0.0%, NA%) | 467363 (2023-03-27) | ||
| Sanofi | 10% Owner | 2020-06-11 | % | 279766 (-30.0%, NA%) | 400000 (2020-05-29) | ||
| Roberts William | VP Reg Dev & Med Safety | 2014-02-06 | % | 72278 (NA%, NA%) | () | ||
| Goldberg Murray A | SVP Administration & Asst Secr | 2014-12-18 | % | 70836 (1.9%, NA%) | 69502 (2014-10-27) | ||
| Stahl Neil | EVP Research and Development | 2024-02-28 | % | 61438 (-1.5%, -1.5%) | 62458 (2024-02-08) |
C: 0 / 1
S: 0 / 8037 P: NA / 950.35 |
C: 0 / 1
S: 0 / 8037 P: NA / 950.35 |
| Murphy Andrew J | EVP Research | 2024-03-15 | % | 52616 (0.0%, 0.0%) | 52616 (2023-12-14) |
C: 0 / 1
S: 0 / 5783 P: NA / 956.47 |
C: 0 / 3
S: 0 / 18811 P: NA / 853.88 |
| Larosa Joseph J | EVP General Counsel and Secret | 2024-02-28 | % | 40265 (-2.3%, -6.8%) | 41265 (2024-02-26) |
C: 0 / 3
S: 0 / 3000 P: NA / 969.22 |
C: 0 / 3
S: 0 / 3000 P: NA / 969.22 |
| Van Plew Daniel P | EVP & General Mgr, Industrial | 2024-02-16 | % | 33838 (-23.5%, 0.0%) | 44272 (2024-02-13) |
C: 0 / 1
S: 0 / 10434 P: NA / 942.28 |
C: 0 / 1
S: 0 / 10434 P: NA / 942.28 |
| Sing George L | Director | 2024-02-28 | % | 28499 (0.0%, 0.0%) | 28499 (2024-02-26) |
C: 0 / 3
S: 0 / 5500 P: NA / 969.09 |
C: 0 / 3
S: 0 / 5500 P: NA / 969.09 |
| Fenimore Christopher R. | SVP Finance & CFO | 2024-02-12 | % | 24431 (-16.7%, -16.7%) | 29350 (2024-01-25) |
C: 0 / 1
S: 0 / 4919 P: NA / 953.31 |
C: 0 / 3
S: 0 / 9297 P: NA / 905.24 |
| Landry Robert E | EVP Finance CFO | 2024-02-06 | % | 23963 (0.5%, 1.0%) | 23844 (2024-02-02) | ||
| Ryan Arthur F | Director | 2024-04-03 | % | 18182 (-0.4%, -1.5%) | 18282 (2024-03-05) |
C: 0 / 3
S: 0 / 300 P: NA / 966.27 |
C: 0 / 6
S: 0 / 600 P: NA / 907.32 |
a Total of direct and indirect accounts with percentage change comparing with (previous report, 3 months ago). The latter is NA when no change was found in the last 3 months.
Notice: Shares amount and percentage change 1) do not reflect intraday conversion and execution of derivative securities. 2) may subject to correction on amendment filing.
b Vital&Spontaneous transactions of the past 3 and 6 months, respectively. For acquisitions, code P (open market purchase), L (small acquisition), and I (at discretion of broker) are counted. For dispositions, code S (open market sell), D (sell back to issuer) and I (at discretion of broker) are counted. "C:" count of number of transactions. "S:" shares amount involved in corrresponding transactions. "P:" average per share price of the transactions (for reference only). Horizontal bar chart denotes shares amount of acquisitions and dispositions. Black thin bar is fixed size ruler for easy comparison between reporters.
c Quantile value of transaction count in b among industry peers, sector peers, and the market, respectively.
d Percentage of transaction shares amount to shares outstanding.
Notice: red exclamation mark (!) represents the reporter has Form 4 amendment filings in the latest three reports.
Non-derivative Transactions Chart
Tips: Click legend to show single series Click any bar to highlight corresponding transaction records
what is this?
Non-derivative Transactions Table
CSV download
Tips: Click legend to show single series Click any bar to highlight corresponding transaction records what is this?
|
|
|
Tips: type "code_p" to show transactions with code "P".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-04-03 | 2024-04-01 | 4 | Mccourt Marion | EVP COMMERCIAL | holding | 158.0 | 0 | 0.01 | 0.0 | By 401(K) Plan | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 107.94 (REGN) | ||
| 2024-04-03 | 2024-04-01 | 2024-04-01 | 4 | Mccourt Marion | EVP COMMERCIAL | dsp | 250.0 | 1.86 | 0.02 | 964.73 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code S | 13181.0 | 107.94 (REGN) |
| 2024-04-03 | 2024-04-01 | 2024-04-01 | 4 | Ryan Arthur F | DIRECTOR | dsp | 100.0 | 0.55 | 0.01 | 962.53 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code S | 18182.0
|
107.94 (REGN) |
| 2024-03-15 | 2024-03-13 | 4 | Murphy Andrew J | EVP RESEARCH | holding | 4310.0 | 0 | 0.4 | 0.0 | By 401(K) Plan | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 107.94 (REGN) | ||
| 2024-03-15 | 2024-03-13 | 2024-03-13 to 2024-03-14 | 4 | Murphy Andrew J | EVP RESEARCH | dsp | 20000.0 | 29.28 | 1.85 | 967.38 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code F S | 48306.0
|
107.94 (REGN) |
| 2024-03-15 | 2024-03-13 | 2024-03-13 | 4 | Murphy Andrew J | EVP RESEARCH | acq | 20000.0 | 29.28 | 1.85 | 399.66 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code M | 68306.0 | 107.94 (REGN) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Ryan Arthur F | DIRECTOR | dsp | 100.0 | 0.54 | 0.01 | 982.05 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code S | 18282.0
|
107.94 (REGN) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Mccourt Marion | EVP COMMERCIAL | dsp | 358.0 | 2.6 | 0.03 | 967.5 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code S | 13431.0 | 107.94 (REGN) |
| 2024-03-05 | 2024-03-01 | 4 | Mccourt Marion | EVP COMMERCIAL | holding | 158.0 | 0 | 0.01 | 0.0 | By 401(K) Plan | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 107.94 (REGN) | ||
| 2024-02-28 | 2024-02-26 | 4 | Larosa Joseph J | EVP GENERAL COUNSEL AND SECRET | holding | 355.0 | 0 | 0.03 | 0.0 | By 401(K) Plan | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 107.94 (REGN) | ||
| 2024-02-28 | 2024-02-26 | 4 | Larosa Joseph J | EVP GENERAL COUNSEL AND SECRET | holding | 3367.0 | 0 | 0.31 | 0.0 | 2022 Grat | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 107.94 (REGN) | ||
| 2024-02-28 | 2024-02-26 | 2024-02-26 | 4 | Larosa Joseph J | EVP GENERAL COUNSEL AND SECRET | dsp | 1000.0 | 2.66 | 0.09 | 990.0 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code S | 36543.0 | 107.94 (REGN) |
| 2024-02-28 | 2024-02-26 | 4 | Stahl Neil | EVP RESEARCH AND DEVELOPMENT | holding | 4605.0 | 0 | 0.43 | 0.0 | By Spouse As Trustee | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 107.94 (REGN) | ||
| 2024-02-28 | 2024-02-26 | 4 | Stahl Neil | EVP RESEARCH AND DEVELOPMENT | holding | 5834.0 | 0 | 0.54 | 0.0 | By 401(K) Plan | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 107.94 (REGN) | ||
| 2024-02-28 | 2024-02-26 | 2024-02-26 | 4 | Stahl Neil | EVP RESEARCH AND DEVELOPMENT | dsp | 1020.0 | 1.96 | 0.09 | 0.0 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code G | 50999.0 | 107.94 (REGN) |
| 2024-02-28 | 2024-02-26 | 4 | Sing George L | DIRECTOR | holding | 400.0 | 0 | 0.04 | 0.0 | By Spouse/Cust Son | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 107.94 (REGN) | ||
| 2024-02-28 | 2024-02-26 | 4 | Sing George L | DIRECTOR | holding | 1000.0 | 0 | 0.09 | 0.0 | By Trust For Son | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 107.94 (REGN) | ||
| 2024-02-28 | 2024-02-26 | 4 | Sing George L | DIRECTOR | holding | 750.0 | 0 | 0.07 | 0.0 | By Spouse | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 107.94 (REGN) | ||
| 2024-02-28 | 2024-02-26 | 2024-02-26 | 4 | Sing George L | DIRECTOR | dsp | 1000.0 | 3.66 | 0.09 | 992.5 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code S | 26349.0
|
107.94 (REGN) |
| 2024-02-28 | 2024-02-26 | 2024-02-26 | 4 | Sing George L | DIRECTOR | acq | 1000.0 | 3.72 | 0.09 | 413.33 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code M | 26849.0
|
107.94 (REGN) |
| 2024-02-26 | 2024-02-22 | 4 | Sing George L | DIRECTOR | holding | 1000.0 | 0 | 0.09 | 0.0 | By Trust For Son | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 107.94 (REGN) | ||
| 2024-02-26 | 2024-02-22 | 4 | Sing George L | DIRECTOR | holding | 400.0 | 0 | 0.04 | 0.0 | By Spouse/Cust Son | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 107.94 (REGN) | ||
| 2024-02-26 | 2024-02-22 | 4 | Sing George L | DIRECTOR | holding | 750.0 | 0 | 0.07 | 0.0 | By Spouse | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 107.94 (REGN) | ||
| 2024-02-26 | 2024-02-22 | 2024-02-22 to 2024-02-23 | 4 | Sing George L | DIRECTOR | dsp | 3500.0 | 11.73 | 0.32 | 967.86 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code S | 26349.0
|
107.94 (REGN) |
| 2024-02-26 | 2024-02-22 | 2024-02-22 to 2024-02-23 | 4 | Sing George L | DIRECTOR | acq | 3500.0 | 13.04 | 0.32 | 413.33 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code M | 26849.0
|
107.94 (REGN) |
| 2024-02-26 | 2024-02-26 | 2024-02-26 | 4 | Bassler Bonnie L | DIRECTOR | acq | 854.0 | 38.19 | 0.08 | 391.92 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code M | 2236.0 | 107.94 (REGN) |
| 2024-02-26 | 2024-02-26 | 2024-02-26 | 4 | Bassler Bonnie L | DIRECTOR | dsp | 854.0 | 38.19 | 0.08 | 979.25 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code S | 1382.0 | 107.94 (REGN) |
| 2024-02-26 | 2024-02-22 | 2024-02-22 | 4 | Larosa Joseph J | EVP GENERAL COUNSEL AND SECRET | dsp | 1000.0 | 2.59 | 0.09 | 967.65 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code S | 37543.0 | 107.94 (REGN) |
| 2024-02-26 | 2024-02-22 | 4 | Larosa Joseph J | EVP GENERAL COUNSEL AND SECRET | holding | 355.0 | 0 | 0.03 | 0.0 | By 401(K) Plan | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 107.94 (REGN) | ||
| 2024-02-26 | 2024-02-22 | 4 | Larosa Joseph J | EVP GENERAL COUNSEL AND SECRET | holding | 3367.0 | 0 | 0.31 | 0.0 | 2022 Grat | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 107.94 (REGN) |
Derivative Transactions Chart
Tips: Click legend to show single series Click any bar to highlight corresponding transaction records
what is this?
Derivative Transactions Table
Tips: Click legend to show single series Click any bar to highlight corresponding transaction records what is this?
|
|
Tips: type "code_m" to show transactions with code "M".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-15 | 2024-03-13 | 2024-03-13 | 4 | Murphy Andrew J | EVP RESEARCH | dsp | 20000.0 | 50.0 | 1.85 | 399.66 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code M | 20000.0 | 107.94 (REGN) |
| 2024-02-28 | 2024-02-26 | 2024-02-26 | 4 | Sing George L | DIRECTOR | dsp | 1000.0 | 15.78 | 0.09 | 413.33 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code M | 5338.0 | 107.94 (REGN) |
| 2024-02-26 | 2024-02-22 | 2024-02-22 to 2024-02-23 | 4 | Sing George L | DIRECTOR | dsp | 3500.0 | 35.58 | 0.32 | 413.33 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code M | 6338.0
|
107.94 (REGN) |
| 2024-02-26 | 2024-02-26 | 2024-02-26 | 4 | Bassler Bonnie L | DIRECTOR | dsp | 854.0 | 100.0 | 0.08 | 391.92 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code M | 0.0 | 107.94 (REGN) |
| 2024-02-20 | 2024-02-15 | 2024-02-15 | 4 | Yancopoulos George | BD. CO-CHAIR, PRESIDENT & CSO | dsp | 172723.0 | 100.0 | 16.0 | 399.66 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code M | 0.0 | 107.94 (REGN) |
| 2024-02-13 | 2024-02-09 | 2024-02-09 | 4 | Van Plew Daniel P | EVP & GENERAL MGR, INDUSTRIAL | dsp | 35375.0 | 100.0 | 3.28 | 378.3 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code M | 0.0
|
107.94 (REGN) |
| 2024-02-12 | 2024-02-08 | 2024-02-08 to 2024-02-09 | 4 | Sing George L | DIRECTOR | dsp | 1000.0 | 9.23 | 0.09 | 413.33 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code M | 9838.0
|
107.94 (REGN) |
| 2024-02-06 | 2024-02-02 | 2024-02-02 | 4 | Stahl Neil | EVP RESEARCH AND DEVELOPMENT | dsp | 30750.0 | 100.0 | 2.85 | 399.66 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code M | 0.0 | 107.94 (REGN) |
| 2024-02-06 | 2024-02-02 | 2024-02-02 | 4 | Landry Robert E | EVP FINANCE CFO | dsp | 400.0 | 3.28 | 0.04 | 378.98 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code M | 11787.0 | 107.94 (REGN) |
| 2024-02-02 | 2024-01-31 | 2024-01-31 | 4 | Landry Robert E | EVP FINANCE CFO | dsp | 400.0 | 3.18 | 0.04 | 378.98 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code M | 12187.0 | 107.13 (REGN) |
| 2024-01-31 | 2024-01-30 | 2024-01-30 | 4 | Bassler Bonnie L | DIRECTOR | dsp | 827.0 | 50.0 | 0.08 | 380.95 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code M | 827.0 | 107.13 (REGN) |
| 2024-01-25 | 2024-01-23 | 2024-01-23 to 2024-01-24 | 4 | Landry Robert E | EVP FINANCE CFO | dsp | 1600.0 | 11.28 | 0.15 | 378.98 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code M | 12587.0
|
107.13 (REGN) |
| 2024-01-25 | 2024-01-23 | 2024-01-23 | 4 | Goldstein Joseph L | DIRECTOR | dsp | 2707.0 | 100.0 | 0.25 | 625.6 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code M | 0.0 | 107.13 (REGN) |
| 2024-01-25 | 2024-01-23 | 2024-01-23 | 4 | Fenimore Christopher R. | SVP CONTROLLER | dsp | 10000.0 | 100.0 | 0.93 | 477.67 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code M | 0.0
|
107.13 (REGN) |
| 2024-01-18 | 2024-01-17 | 2024-01-17 | 4 | Landry Robert E | EVP FINANCE CFO | dsp | 500.0 | 3.4 | 0.05 | 378.98 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code M | 14187.0 | 107.13 (REGN) |
| 2024-01-17 | 2024-01-12 | 2024-01-12 | 4 | Landry Robert E | EVP FINANCE CFO | dsp | 800.0 | 5.17 | 0.07 | 378.98 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code M | 14687.0 | 107.13 (REGN) |
| 2024-01-08 | 2024-01-04 | 2024-01-04 | 4 | Landry Robert E | EVP FINANCE CFO | dsp | 500.0 | 3.13 | 0.05 | 378.98 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code M | 15487.0 | 107.13 (REGN) |
| 2024-01-04 | 2024-01-03 | 2024-01-03 | 4 | Fenimore Christopher R. | SVP CONTROLLER | dsp | 10000.0 | 66.67 | 0.93 | 477.67 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code M | 5000.0
|
107.13 (REGN) |
| 2024-01-04 | 2024-01-02 | 2024-01-02 | 4 | Thompson Craig B. | DIRECTOR | acq | 1607.0 | 100.0 | 0.15 | 888.34 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code A | 1607.0 | 107.13 (REGN) |
| 2024-01-04 | 2024-01-02 | 2024-01-02 | 4 | Goldstein Joseph L | DIRECTOR | acq | 1607.0 | 100.0 | 0.15 | 888.34 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code A | 1607.0 | 107.13 (REGN) |
| 2024-01-04 | 2024-01-02 | 2024-01-02 | 4 | Poon Christine A | DIRECTOR | acq | 1607.0 | 100.0 | 0.15 | 888.34 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code A | 1607.0 | 107.13 (REGN) |
| 2024-01-04 | 2024-01-02 | 2024-01-02 | 4 | Coles N Anthony | DIRECTOR | acq | 1607.0 | 100.0 | 0.15 | 888.34 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code A | 1607.0 | 107.13 (REGN) |
| 2024-01-04 | 2024-01-02 | 2024-01-02 | 4 | Brown Michael S | DIRECTOR | acq | 1607.0 | 100.0 | 0.15 | 888.34 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code A | 1607.0 | 107.13 (REGN) |
| 2024-01-04 | 2024-01-02 | 2024-01-02 | 4 | Ryan Arthur F | DIRECTOR | acq | 1607.0 | 100.0 | 0.15 | 888.34 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code A | 1607.0 | 107.13 (REGN) |
| 2024-01-04 | 2024-01-02 | 2024-01-02 | 4 | Schenkein David P | DIRECTOR | acq | 508.0 | 100.0 | 0.05 | 888.34 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code A | 508.0 | 107.13 (REGN) |
| 2024-01-04 | 2024-01-02 | 2024-01-02 | 4 | Zoghbi Huda Y | DIRECTOR | acq | 1607.0 | 100.0 | 0.15 | 888.34 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code A | 1607.0 | 107.13 (REGN) |
| 2024-01-04 | 2024-01-02 | 2024-01-02 | 4 | Zoghbi Huda Y | DIRECTOR | dsp | 1117.0 | 100.0 | 0.1 | 391.92 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code M | 0.0 | 107.13 (REGN) |
| 2024-01-04 | 2024-01-03 | 2024-01-03 | 4 | Larosa Joseph J | EVP GENERAL COUNSEL AND SECRET | dsp | 34000.0 | 100.0 | 3.17 | 399.66 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code M | 0.0 | 107.13 (REGN) |
| 2024-01-04 | 2024-01-02 | 2024-01-02 | 4 | Guarini Kathryn | DIRECTOR | acq | 508.0 | 100.0 | 0.05 | 888.34 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code A | 508.0 | 107.13 (REGN) |
| 2024-01-04 | 2024-01-02 | 2024-01-02 | 4 | Sing George L | DIRECTOR | acq | 1607.0 | 100.0 | 0.15 | 888.34 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code A | 1607.0 | 107.13 (REGN) |
Form 3 CSV download
| Filing Date | Date requiring statement | Form Type | Reporter | Relation | Amounta | ‱(SO)c | Avg Excercisable Prcd | Account | Type | Full Name | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-08 | 2024-02-06 | 3 | PITOFSKY JASON | Vice President, Controller | 4204.0 | 0.39 | 0.0 | Direct | common stock | REGENERON PHARMACEUTICALS, INC. | 107.94 (REGN) |
| 2024-02-08 | 2024-02-06 | 3 | PITOFSKY JASON | Vice President, Controller | 11612.0
|
1.08 | 692.2 | Direct | non-qualified stock option (right to buy) | REGENERON PHARMACEUTICALS, INC. | 107.94 (REGN) |
a Sum of same type of securities in the form
b Relative to reporter's shares owned before (disposition) or after (acquisition) operation
c Relative to issuer's shares outstanding (1/10000)
d Average price for securities of the same type. Check the original form for detailed prices of multiple transactions
e Documented shares outstanding closest to the transaction date
Note: Corporate may change mapped CIK when merge or spin-off happen. Please report error if the ticker you searched for does not have up-to-date insider trading information.
Show up to 30 records per table for current tier. (Access Guide)